| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abandoning diesel because of health perspectives: are there reasonable alternatives?
|
Vreugdenhil, G.
|
|
|
27 |
7 |
p. 1360-1361
|
artikel
|
| 2 |
Activity of immune checkpoint inhibition in platinum refractory germ-cell tumors
|
Zschäbitz, S.
|
|
|
27 |
7 |
p. 1356-1360
|
artikel
|
| 3 |
A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC)
|
Oki, E.
|
|
|
27 |
7 |
p. 1266-1272
|
artikel
|
| 4 |
A tribute to the life and career of Holbrook Kohrt
|
Marabelle, A.
|
|
|
27 |
7 |
p. 1183-1184
|
artikel
|
| 5 |
Biomarkers associated with checkpoint inhibitors
|
Manson, G.
|
|
|
27 |
7 |
p. 1199-1206
|
artikel
|
| 6 |
Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas
|
Ruan, J.
|
|
|
27 |
7 |
p. 1226-1234
|
artikel
|
| 7 |
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers
|
Drilon, A.
|
|
|
27 |
7 |
p. 1286-1291
|
artikel
|
| 8 |
Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL
|
Koch, K.
|
|
|
27 |
7 |
p. 1323-1329
|
artikel
|
| 9 |
CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)—Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
|
Schmidt-Hieber, M.
|
|
|
27 |
7 |
p. 1207-1225
|
artikel
|
| 10 |
Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes
|
Chung, J.H.
|
|
|
27 |
7 |
p. 1336-1341
|
artikel
|
| 11 |
Corrections to “Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials”
|
Ramalingam, S.S.
|
|
|
27 |
7 |
p. 1363
|
artikel
|
| 12 |
Corrections to “Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies”
|
Naidoo, J.
|
|
|
27 |
7 |
p. 1362
|
artikel
|
| 13 |
Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies
|
Sanmamed, M.F.
|
|
|
27 |
7 |
p. 1190-1198
|
artikel
|
| 14 |
Editorial Board
|
|
|
|
27 |
7 |
p. ii-iii
|
artikel
|
| 15 |
Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study † † Presented in part at the 2013 and 2014 San Antonio Breast Cancer Symposiums.
|
Jacot, W.
|
|
|
27 |
7 |
p. 1235-1241
|
artikel
|
| 16 |
Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA
|
Houot, R.
|
|
|
27 |
7 |
p. 1349-1350
|
artikel
|
| 17 |
Insertion of central venous catheters (CVCs): any changes in the past 10 years?
|
Biffi, R.
|
|
|
27 |
7 |
p. 1351
|
artikel
|
| 18 |
Oral health and risk of colorectal cancer: results from three cohort studies and a meta-analysis
|
Ren, H.G.
|
|
|
27 |
7 |
p. 1329-1336
|
artikel
|
| 19 |
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study
|
Folprecht, G.
|
|
|
27 |
7 |
p. 1273-1279
|
artikel
|
| 20 |
Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes
|
Cheah, C.Y.
|
|
|
27 |
7 |
p. 1317-1323
|
artikel
|
| 21 |
Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma
|
Vallet, H.
|
|
|
27 |
7 |
p. 1352-1353
|
artikel
|
| 22 |
Pemetrexed plus carboplatin versus pemetrexed in pretreated patients with advanced non-squamous non-small-cell lung cancer: treating the right patients based on individualized treatment effect prediction †
|
van Kruijsdijk, R.C.M.
|
|
|
27 |
7 |
p. 1280-1286
|
artikel
|
| 23 |
Pragmatic randomized clinical trials: a proposal to enhance evaluation of new cancer therapies with early signs of exceptional activity
|
Koehler, M.
|
|
|
27 |
7 |
p. 1342-1348
|
artikel
|
| 24 |
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence
|
Mittendorf, E.A.
|
|
|
27 |
7 |
p. 1241-1248
|
artikel
|
| 25 |
Reply to the letter to the editor ‘Abandoning diesel because of health perspectives: are there reasonable alternatives?’ by Vreugdenhil and Mannaerts
|
Swanton, C.
|
|
|
27 |
7 |
p. 1361
|
artikel
|
| 26 |
Reply to the letter to the editor ‘Insertion of central venous catheters (CVCs): any changes in the past ten years’ by Biffi et al.
|
Pinto, D.
|
|
|
27 |
7 |
p. 1351-1352
|
artikel
|
| 27 |
Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma
|
Nadal, R.
|
|
|
27 |
7 |
p. 1304-1311
|
artikel
|
| 28 |
Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment † † Note on previous publication of this work: Part of this work was presented as poster presentation at the 25. Deutscher Hautkrebskongress (25. German Skin Cancer Congress), 10–12 September 2015 in Munich, Germany. The abstract was published in the online portal of JDDG. See ref. [1].
|
Bender, C.
|
|
|
27 |
7 |
p. 1353-1354
|
artikel
|
| 29 |
Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases
|
Kanai, O.
|
|
|
27 |
7 |
p. 1354-1356
|
artikel
|
| 30 |
Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma
|
Matsuo, K.
|
|
|
27 |
7 |
p. 1257-1266
|
artikel
|
| 31 |
Statistical controversies in clinical research: the importance of importance
|
Gleiss, A.
|
|
|
27 |
7 |
p. 1185-1189
|
artikel
|
| 32 |
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
|
Chatterjee, M.
|
|
|
27 |
7 |
p. 1291-1298
|
artikel
|
| 33 |
Table of Contents
|
|
|
|
27 |
7 |
p. iv-vi
|
artikel
|
| 34 |
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study †
|
Martin, M.
|
|
|
27 |
7 |
p. 1249-1256
|
artikel
|
| 35 |
Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA)
|
Tandstad, T.
|
|
|
27 |
7 |
p. 1299-1304
|
artikel
|
| 36 |
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment
|
Pouessel, D.
|
|
|
27 |
7 |
p. 1311-1316
|
artikel
|
Tijdschrift beschrijving